Cell and Gene Therapy Companies Europe

Cell and gene therapy programmes moving into clinical and commercial stages continue to pressure manufacturing systems, where scalability, regulatory readiness and process consistency remain critical challenges in viral vector production.

As these pressures increase, OXB supports developers through viral vector manufacturing and process development spanning early-stage programmes through commercial supply. It is a quality and innovation-led cell and gene therapy CDMO providing end-to-end services from preclinical development through commercial launch. More than 85 client programmes, over 1,000 GMP batches and upwards of 45 regulatory submissions reflect the operational scale supporting its activities.
Originally established as a spinout from the University of Oxford, OXB has developed capabilities around lentiviral vector manufacturing and broader viral vector technologies used in advanced therapies. The company’s work spans process development, analytical support, GMP manufacturing and regulatory support for cell and gene therapy developers operating across multiple therapeutic areas.

Integrated Viral Vector Production

Manufacturing consistency remains one of the central operational challenges in cell and gene therapy. Viral vector production requires alignment between upstream processing, purification, analytics and fill-finish activities, particularly as therapies move into larger patient populations and commercial manufacturing volumes. OXB integrates these activities through platform-based manufacturing systems developed for lentiviral and adeno-associated viral vectors.

Its LentiVector™ platform combines vector design, upstream and downstream processing, analytical testing and GMP manufacturing within a unified production structure. The platform incorporates technologies including suspension and perfusion processes, scalable producer cell lines and proprietary vector systems intended to improve productivity, purity and manufacturing reproducibility.

Cell and gene therapy is starting to shift from high-risk experimental science into something much closer to a scalable healthcare market. Across Europe, advanced therapies that once existed largely inside research programmes are moving into approved treatment pathways, commercial manufacturing environments and hospital networks preparing for long-term deployment. The pace is still uneven, but the direction is becoming harder to ignore.

What makes the sector so closely watched is the scale of what these therapies are attempting to address. Cell therapies use living cells to restore immune function or repair damaged tissue, while gene therapies target disease at the molecular level by modifying or replacing defective genes. The field now includes CAR T-cell therapies, stem cell platforms, viral vector systems and newer gene-editing technologies pushing deeper into oncology, regenerative medicine and rare disease treatment.

The commercial opportunity surrounding that science has expanded quickly despite financial pressure across broader biotechnology markets. Industry forecasts continue projecting that the global cell and gene therapy sector could surpass $100 billion during the next decade as regulatory approvals increase and clinical adoption widens. Investors and pharmaceutical companies are still treating the category cautiously in some areas, but the market no longer feels speculative in the way it did several years ago.

Europe remains one of the industry’s most important operating environments because of its research infrastructure, pharmaceutical manufacturing base and academic networks. Germany, the UK, France and Switzerland continue attracting investment across translational medicine, clinical development and advanced manufacturing capacity. The region also benefits from long-standing collaboration between universities, biotechnology companies and healthcare systems, which has helped accelerate movement from laboratory research into clinical application.

Regulation has evolved alongside the science. The European Medicines Agency has expanded engagement around advanced therapy medicinal products, or ATMPs, creating faster evaluation pathways while maintaining strict oversight around safety and manufacturing standards. For developers, regulatory clarity matters almost as much as scientific progress because commercialisation timelines remain heavily tied to approval efficiency.

Cancer treatment continues driving much of the sector’s commercial momentum. CAR T-cell therapies have shown particularly strong results in certain blood cancers, especially among patients who exhausted conventional treatment options earlier in their care journey. Healthcare providers and pharmaceutical companies are now focused on reducing manufacturing turnaround times and expanding treatment availability beyond a limited number of specialist centres.

Rare disease treatment is creating another major growth area. Many gene therapies are designed around inherited conditions where existing treatment options are limited or entirely absent. That is forcing healthcare systems into difficult reimbursement discussions because several therapies involve high upfront pricing in exchange for potentially long-term or even permanent therapeutic benefit. Traditional reimbursement structures were not designed for one-time treatments carrying such substantial initial costs.

Manufacturing has become one of the defining commercial challenges across the industry. Cell and gene therapies require highly controlled production environments, strict quality oversight and specialised logistics infrastructure. Scaling those operations while maintaining regulatory compliance remains difficult, particularly for therapies tied to individualised patient treatment processes.

Supply chain reliability carries unusual importance in this sector because many therapies are highly time-sensitive. Delays involving cold-chain logistics, manufacturing schedules or patient coordination can directly affect treatment viability. Unlike conventional pharmaceutical products, many advanced therapies cannot tolerate major disruptions once production begins.

Healthcare systems across Europe are responding by increasing investment in specialised treatment infrastructure. Interest in automation and digitally managed manufacturing environments is also rising as companies look for ways to improve consistency, reduce production variability and support larger therapy volumes without compromising regulatory standards.

Partnership activity continues accelerating across the market. Pharmaceutical companies are collaborating more aggressively with biotechnology firms, research institutions and contract manufacturing organisations as they attempt to strengthen both clinical pipelines and production capabilities. Few companies can independently manage every stage of development, manufacturing and commercialisation inside such a technically demanding environment.

Pricing remains one of the sector’s most politically sensitive issues. Advanced therapies often involve substantial upfront costs because of their complexity, manufacturing requirements and personalised treatment design. European healthcare systems are increasingly exploring outcome-based reimbursement structures and long-term payment models as they attempt to balance innovation access against mounting budget pressure.

Workforce shortages are adding another layer of strain. Cell and gene therapy manufacturing depends on highly specialised expertise spanning molecular biology, bioprocessing, regulatory affairs and clinical manufacturing operations. Competition for experienced talent has intensified as more companies expand production facilities across Europe simultaneously.

Regulatory fragmentation across Europe still complicates commercialisation despite broader progress around approvals. Companies often face different reimbursement rules, manufacturing expectations and clinical access frameworks across national healthcare systems, slowing expansion even after therapies receive regulatory clearance.Infrastructure readiness also varies considerably between markets. Advanced therapies typically require

specialist treatment centres, trained clinicians and long-term patient monitoring systems. Larger healthcare networks are generally better positioned to support commercial deployment at scale, while smaller systems may struggle with both operational capacity and funding requirements.

The market is beginning to distinguish more clearly between companies built around research milestones and those capable of sustained commercial execution. Manufacturing scalability, supply continuity, regulatory coordination and post-treatment monitoring are becoming just as important as scientific innovation itself. Healthcare providers and pharmaceutical partners increasingly want assurance that therapies can move reliably from laboratory success into real-world delivery environments.

The next stage of the sector will likely revolve around accessibility, production efficiency and cost reduction. Interest is growing around allogeneic therapies, automated manufacturing systems and newer gene-editing technologies that could simplify production and shorten treatment timelines over the coming years.

Europe is expected to remain one of the industry’s strongest regions because of continued research investment and increasingly coordinated relationships between regulators, healthcare systems and biotechnology companies. Policy decisions made during the next several years will play a major role in determining how quickly advanced therapies move into mainstream treatment pathways.

Cell and gene therapy is no longer discussed purely as a future category inside biotechnology. It is becoming a more established part of modern medicine, particularly in areas where conventional treatment options remain limited or ineffective.

Healthcare organisations evaluating cell and gene therapy providers in 2026 are looking beyond scientific innovation alone. Manufacturing reliability, regulatory strength, treatment accessibility and long-term clinical value are becoming equally important in a market moving steadily towards commercial maturity.

In recent years, cell and gene therapies have been redefining the treatment paradigm in a number of disease areas. These therapies offer the potential to change the lives of patients suffering from previously incurable conditions. Santen being a company focused on ophthalmology, fully committed to reducing the loss of social and economic opportunities for people with eye conditions, it feels natural as well as necessary for us to expand into this promising field.

For the past 130 years, Santen has been contributing to people’s eye health, expanding to cover over 60 countries and reaching the number 1 position in the Japanese and Chinese ophthalmic markets. As part of our new vision towards 2030, we are focusing on building our capabilities in order to leverage new technological advancements. We recently established a dedicated, global Cell & Gene Therapy business unit, committed to changing the lives of patients with inherited retinal diseases through transformative solutions.

As we create a high-performing, sustainable and scalable platform for cell and gene therapies, we have aimed to maintain an intricate balance between leveraging the expertise and footprint we benefit from as an established, specialized pharmaceutical company, and developing new skills and capabilities to ensure we are able to tackle the unique challenges linked to this field.

The cell and gene therapy field is evolving rapidly and represents higher risks compared to existing technologies. Developing such therapies therefore requires an agile, adaptable and risk-tolerant mindset. We have built an incredibly diverse team with deep expertise and experience across the ophthalmology, retina and rare disease fields. Team members already have experience dealing with the unique go to market approach required for cell and gene therapies, linked to, for example the small patient population associated with rare diseases.